Renal toxicity associated with disease-modifying antirheumatic drugs used for the treatment of rheumatoid arthritis

Seminars in Arthritis and Rheumatism

Volumn 30, Issue 3, 2000, Pages 196-208

  Schiff, Michael H ^a,b   Whelton, Andrew ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

DMARDs; Drug drug interactions; Renal toxicity; Rheumatoid arthritis

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AUROTHIOMALATE; AZATHIOPRINE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD DERIVATIVE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; CYTOPENIA; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; GLOMERULONEPHRITIS; HEMATURIA; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; NEPHROTOXICITY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; RHEUMATOID ARTHRITIS; STOMATITIS; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0033638297     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1053/sarh.2000.16641     Document Type: Review

References (75)

1. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis
2. Longterm therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone
3. Interstitial nephritis, the nephrotic syndrome, and chronic renal failure secondary to non-steroidal anti-inflammatory drugs
4. The mechanism of action of FK-506 and cyclosporin A
5. Cyclosporin A treatment of refractory rheumatoid arthritis
6. Effects of cyclosporin on serum creatinine in patients with rheumatoid arthritis
7. Cyclosporin A in severe, treatment-refractory rheumatoid arthritis
8. The effect of cyclosporin on renal function
9. Renal morphology after cyclosporin A therapy in rheumatoid arthritis patients
10. Risk factor for cyclosporine-induced nephropathy in patients with autoimmune diseases
11. Morphological and functional renal effects of long-term low-dose cyclosporin A treatment in patients with rheumatoid arthritis
12. Renal biopsy findings and follow-up of renal function in rheumatoid arthritis patients treated with cyclosporin A: An update form the International Kidney Biopsy Registry
13. Longterm, low dose cyclosporine in patients with rheumatoid arthritis: Renal function loss without structural nephropathy
14. Cyclosporin in rheumatoid arthritis: A double blind, placebo-controlled study in 52 patients
15. A study of the long-term efficacy and toxicity of cyclosporin A in rheumatoid arthritis
16. Cyclosporin in common clinical practice: An estimation of the benefit/risk ratio in patients with rheumatoid arthritis
17. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine: Results of a 48-week multicenter study comparing low-dose cyclosporine and placebo
18. Interaction of cyclosporine A and non-steroidal anti-inflammatory drugs on renal function in patients with rheumatoid arthritis
19. US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis
20. Disease-modifying antirheumatic drugs: Potential effects in older patients
21. Modifying effects of amlodipine on cyclosporin A-induced changes in renal function in patients with psoriasis
22. Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: A randomised trial
23. Gold nephropathy
24. The natural course of gold nephropathy: A long-term study of 21 patients
25. The natural course of gold and penicillamine nephropathy: A longterm study of 54 patients
26. Membranous nephropathy in patients with rheumatoid arthritis: Relationship to gold therapy
27. Mild mesangial glomerulopathy: A frequent finding in patients with hematuria or proteinuria
28. Long term chrysotherapy
29. Renal vein thrombosis associated with nephrotic syndrome and gold therapy in rheumatoid arthritis
30. Gold nephropathy in juvenile rheumatoid arthritis
31. Selective concentration and localization of gold in macrophages of synovial and other tissues during and after chrysotherapy in rheumatoid patients
32. Complement C4 null alleles as a marker of gold or D-penicillamine toxicity in the treatment of rheumatoid arthritis
33. Auranofin therapy in rheumatoid arthritis
34. Randomized trial of switching rheumatoid arthritis patients in remission with injectable gold to auranofin
35. Adverse effects of D-penicillamine in rheumatoid arthritis
36. Toxicity of D-penicillamine in rheumatoid arthritis: A report of 63 patients including two with aplastic anemia and one with nephrotic syndrome
37. The toxicity pattern of D-penicillamine therapy: A guide to its use in rheumatoid arthritis
38. Penicillamine-induced proteinuria: Risk factors
39. Low-dose penicillamine treatment of RA: Comparison of 300 mg and 600 mg regimens
40. Efficacy and toxicity of D-penicillamine for rheumatoid disease in the elderly
41. Penicillamine nephropathy in rheumatoid arthritis: A clinical, pathological, and immunological study
42. Natural course of penicillamine nephropathy: A long term study of 33 patients
43. Adverse reactions to D-penicillamine after gold toxicity
44. Effect of penicillamine on the kidney
45. Low-dose D-penicillamine therapy in rheumatoid arthritis
46. Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate
47. Renal effects of leflunomide compared with other agents used to treat rheumatoid arthritis (RA). XIV EULAR Congress Abstract Book
48. Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral methotrexate: Association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy
49. Renal effects of low dose methotrexate in rheumatoid arthritis
50. The effect of age on methotrexate efficacy and toxicity
51. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis
52. Rheumatoid arthritis: Treatment with azathioprine (Imuran): Clinical side effects and laboratory abnormalities
53. Toxic effects of azathioprine in rheumatoid arthritis
54. Dose refinement in long-term therapy of rheumatoid arthritis with antimalarials
55. Antimalarial drug-induced decrease in creatinine clearance
56. Sulfasalazine in early rheumatoid arthritis
57. Response to sulfasalazine in rheumatoid arthritis: Life table analysis of a 5-year follow-up
58. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase
59. Mechanism of action of leflunomide in rheumatoid arthritis
60. Importance of ribonucleotide availability to proliferating T lymphocytes from healthy humans: Disproportionate expansion of pyrimidine pools and contrasting effects of de novo synthesis inhibitors
61. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomized, multicentre trial
62. TNF-α: A pivotal role in rheumatoid arthritis?
63. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial
64. Long-term use of etanercept in patients with DMARD-refractory rheumatoid arthritis
65. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
66. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis
67. Guidelines for the management of rheumatoid arthritis
68. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: Physiologic foundations and clinical implications
69. Nonsteroidal anti-inflammatory drugs and acute renal failure in the elderly: A risk-benefit assessment
70. Renal papillary necrosis due to naproxen
71. Termination of slow-acting antirheumatic therapy in rheumatoid arthritis
72. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications
73. Combination therapy with cyclosporin and methotrexate in severe rheumatoid arthritis
74. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis